Creativ-Ceutical, 500 Lake Cook Road #350, Deerfield, IL, USA.
Takeda Pharmaceuticals International, Inc. Deerfield, IL, USA.
Eur Neuropsychopharmacol. 2014 Jan;24(1):133-41. doi: 10.1016/j.euroneuro.2013.11.001. Epub 2013 Nov 11.
As more evidence points to the association of cognitive dysfunction with mental health disorders, the assessment of cognitive function in routine clinical care of these disorders is increasingly important. Despite this, it remains unknown how cognitive function is measured in routine clinical practice. The objective of this study was to assess psychiatrists' awareness of cognitive dysfunction in mental health disorders and their methods of cognitive assessment. An online survey was disseminated to psychiatrists in Europe, Asia, Australia and the United States. The survey asked about their perceptions of cognitive dysfunction in several mental health disorders, knowledge of cognitive assessment, method of cognitive assessment, and instruments used to measure cognitive function. Among the 61 respondents, most perceived that schizophrenia was associated with the greatest cognitive dysfunction. Many were unaware whether guidelines were available on cognitive assessment. In schizophrenia, 59% of psychiatrists reportedly used cognitive instruments, while the remainder relied solely on patient history interviews. The use of instruments to assess cognition in major depressive disorder (MDD) and bipolar disorder (BPD) was lower, 38% and 37% respectively. Of the reported instruments used, only a few were actually appropriate for use in the diseases of interest (12% in schizophrenia, 3% in MDD and 0% in BPD). Other instruments reported were clinical measures that did not assess cognition. These findings reveal some inconsistencies in psychiatrists' routine clinical evaluation of cognitive function. There appeared to be low use of true cognitive assessment instruments in clinical practice and confusion regarding what constituted a cognitive assessment instrument.
随着越来越多的证据表明认知功能障碍与精神健康障碍有关,在这些障碍的常规临床护理中评估认知功能变得越来越重要。尽管如此,目前尚不清楚在常规临床实践中如何衡量认知功能。本研究旨在评估精神科医生对精神健康障碍中认知功能障碍的认识及其认知评估方法。我们向欧洲、亚洲、澳大利亚和美国的精神科医生分发了在线调查。该调查询问了他们对几种精神健康障碍中认知功能障碍的看法、对认知评估的了解、认知评估方法以及用于测量认知功能的工具。在 61 名受访者中,大多数人认为精神分裂症与最大的认知功能障碍有关。许多人不知道是否有关于认知评估的指南。在精神分裂症中,据报道 59%的精神科医生使用认知工具,而其余的则仅依赖于患者病史访谈。用于评估重度抑郁症(MDD)和双相情感障碍(BPD)认知功能的工具的使用较少,分别为 38%和 37%。在所报告的使用的仪器中,只有少数真正适合用于所关注的疾病(精神分裂症为 12%,MDD 为 3%,BPD 为 0%)。其他报告的仪器是临床测量工具,不评估认知功能。这些发现揭示了精神科医生在常规临床评估认知功能方面的一些不一致之处。在临床实践中似乎很少使用真正的认知评估工具,并且对于什么是认知评估工具存在混淆。